The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Staff Says Amgen Biosimilar ‘Highly Similar’ to AbbVie’s Humira

FDA Staff Says Amgen Biosimilar ‘Highly Similar’ to AbbVie’s Humira

July 8, 2016 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—Amgen Inc’s biosimilar form of AbbVie Inc.’s adalimumab (Humira) arthritis drug, the world’s top-selling medicine, is similarly potent and safe as the original product, according to a preliminary review by staff members of the U.S. Food and Drug Administration (FDA).

You Might Also Like
  • FDA Panel Backs Amgen Biosimilar of Humira
  • Amgen Files for U.S. Approval of Biosimilar
  • FDA Approves Adalimumab-atto, a Biosimilar of Humira

The assessment precedes an all-day meeting on Tuesday of an independent panel of medical advisers who will decide whether to recommend approval of Amgen’s cheaper version of Humira, called ABP 501. In two large Amgen-sponsored studies, the company says it showed similar effectiveness to Humira.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In documents posted on the FDA’s website on Friday, staff scientists said their review of data from those trials and other studies suggested ABP 501 and Humira are “highly similar” in their safety, purity and potency in the studied indications of rheumatoid arthritis and plaque psoriasis.

The staff’s lengthy briefing report said Amgen’s data also supported use of the biosimilar to treat other diseases for which Humira is approved.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: ABP 501, Amgen, FDA, Food and Drug Administration, plaque psoriasis, Rheumatoid Arthritis (RA)

You Might Also Like:
  • FDA Panel Backs Amgen Biosimilar of Humira
  • Amgen Files for U.S. Approval of Biosimilar
  • FDA Approves Adalimumab-atto, a Biosimilar of Humira
  • Adalimumab-atto, Biosimilar to Humira, Receives FDA Approval

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)